Compare Quest Diagnostics Inc (DGX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs TotalEnergies SE — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while TotalEnergies SE trades at $86.11 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 7.5× Quest Diagnostics Inc's market cap, and TotalEnergies SE pays the higher dividend (4.93%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and TotalEnergies SE for 90 Days on average.
| DGX | TTE | |
|---|---|---|
Market Cap | $25.48B | $191.82B |
Volume | 941,866 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $247.45 | $93.60 |
52-Week Low | $173.49 | $57.39 |
Typical Hold Time | 56 Days | 90 Days |
Enterprise Value | $31.23B | $222.81B |
Dividend Yield | 1.49% | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
TotalEnergies SE (TTE) trades at $86.11, up 2.23% today, with a bearish technical signal but strong fundamentals including a P/E of 10.77 and net income margin of 9.08%. Recent earnings show beats in Q1 and Q2 2026, while Q4 2025 missed expectations. The company announced a $10 billion investment in Argentina and increased share buybacks to $2.5 billion, signaling growth commitment amid stable cash flows.
The outlook is positive with a consensus price target of $95.33, representing 10.7% upside, supported by 55.88% analyst buy ratings. Risks include revenue declines from $263.3B in 2022 to $182.3B in 2025 and geopolitical exposure, but diversification and dividend growth plans offer resilience for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
